AHA shares proposals to lower Medicare drug prices with Congress

In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
The Senate narrowly passed the One Big Beautiful Bill Act (H.R. 1) on July 1 by a 50-50 tally, with Vice President J.D. Vance casting the tie-breaking vote.…
Headline
The AHA June 29 sent a letter to senators urging them to amend the budget reconciliation bill before its final passage in the Senate. The Senate version of the…
Chairperson's File
Advocacy is a core part of the work of the AHA, protecting and sustaining what hospitals and health systems need to truly care for our communities. We often…
Perspective
In the next few days, Senate Republican leaders plan to unveil and vote on their updated reconciliation bill, which, as currently constructed, would have far-…
Headline
The AHA today commented to House and Senate appropriations committee leaders on funding for health care programs in the fiscal year 2026 appropriations bill.…
Headline
Coalition ad links decisions on Medicaid cuts by Congress to impacts on hospitalsA new television and digital advertisement launched today by the Coalition to…